Quince Therapeutics, Inc. (QNCX)
Healthcare
Biotechnology
23.40 $
+1.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Quince Therapeutics, Inc. (QNCX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.8% of the shares are freely tradable; institutional investors hold 17.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
17.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.4%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
74.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
1Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Woodline Partners LP | 2.66 | 5,200,000 | +167.8 | 03/31/2026 |
| Millennium Management LLC | 1.28 | 2,503,717 | +110.3 | 03/31/2026 |
| Vanguard Group Inc | 1.07 | 2,084,015 | +18.2 | 12/31/2025 |
| Shay Capital LLC | 0.91 | 1,772,909 | +0.0 | 03/31/2026 |
| Acadian Asset Management LLC | 0.90 | 1,750,862 | +0.0 | 03/31/2026 |
| Almitas Capital LLC | 0.48 | 930,134 | -6.0 | 12/31/2025 |
| IEQ CAPITAL, LLC | 0.31 | 600,105 | -38.7 | 03/31/2026 |
| BlackRock Inc | 0.24 | 473,259 | +0.3 | 03/31/2026 |
| Vanguard Capital Management, LLC | 0.24 | 461,477 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Extended Market Index | 0.27 | 52,017 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.